Acadia Pharmaceuticals traded at $14.63 this Thursday December 8th, decreasing $0.03 or 0.20 percent since the previous trading session. Looking back, over the last four weeks, Acadia Pharmaceuticals lost 2.21 percent. Over the last 12 months, its price fell by 35.32 percent. Looking ahead, we forecast Acadia Pharmaceuticals to be priced at 15.25 by the end of this quarter and at 13.81 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 9,543.00 -86.00 -0.89% 42.14%
Acadia Pharmaceuticals 14.63 -0.03 -0.20% -35.32%
ALKERMES 25.48 0.21 0.83% 13.95%
Alnylam Pharmaceuticals 238.01 6.68 2.89% 38.00%
Aptinyx Inc 0.24 -0.01 -2.28% -91.38%
Biogen 289.10 -3.05 -1.04% 24.38%
BioMarin Pharmaceutical 104.39 0.70 0.68% 21.92%
Bristol-Myers Squibb 79.88 -0.05 -0.06% 38.83%
Cara Therapeutics 12.23 -0.20 -1.61% -1.13%
Corcept Therapeutics 23.01 -0.51 -2.17% 34.56%
Cytokinetics 36.00 -1.04 -2.81% 2.77%
Intercept Pharmaceuticals 14.70 0.25 1.73% 0.93%
Incyte Corp 84.11 0.08 0.10% 26.54%
Intra Cellular Therapies 51.81 -2.28 -4.22% 37.39%
J&J 177.20 0.03 0.02% 6.81%
Eli Lilly 371.79 -0.18 -0.05% 53.06%
Moderna Inc 184.70 5.70 3.18% -32.15%
Marinus Pharmaceuticals 4.23 0.21 5.22% -60.61%
Neurocrine Biosciences 120.39 -1.12 -0.92% 47.50%
Pfizer 51.78 1.54 3.07% -0.58%
Prothena 59.17 -0.41 -0.69% 31.49%
PTC Therapeutics 38.28 -1.13 -2.87% 6.48%
Ultragenyx Pharmaceutical 41.21 1.70 4.30% -47.50%
Seattle Genetics 125.24 5.88 4.93% -13.60%
Sarepta Therapeutics 119.34 -0.42 -0.35% 39.64%
Vanda Pharmaceuticals 10.83 -0.01 -0.09% -31.33%
Vertex Pharmaceuticals 321.32 3.74 1.18% 54.44%

Indexes Price Day Year
USND 11082 123.45 1.13% -28.58%
US2000 1818 11.39 0.63% -18.10%

Acadia Pharmaceuticals
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).